查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1508422

膀胱癌治疗市场 - 全球产业分析、规模、份额、成长、趋势和预测，2024-2034 年

Bladder Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 136 Pages | 商品交期: 2-10个工作天内

价格

膀胱癌治疗市场 - 报告范围

TMR 关于全球膀胱癌治疗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。期间的市场，考虑2024年为基准年，2034年为预测年。该报告也提供了2024年至2034年全球膀胱癌治疗市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解膀胱癌治疗市场。

市场概况
2023年市场价值 2.714 亿美元
2034 年市场价值 4.563 亿美元
复合年增长率 4.8%

该报告深入探讨了全球膀胱癌治疗市场的竞争格局。全球膀胱癌治疗市场的主要参与者已经确定，并且每一位参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球膀胱癌治疗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依治疗类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依治疗类型，2020-2034
    • 化疗
    • 免疫疗法
    • 标靶治疗
    • 手术
    • 放射治疗
    • 其他（联合疗法等）
  • 市场吸引力：按治疗类型分类

第 7 章：全球市场分析与预测：按膀胱癌类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按膀胱癌类型，2020-2034年
    • 非肌肉层浸润性膀胱癌 (NMIBC)
    • 肌肉浸润性膀胱癌 (MIBC)
  • 市场吸引力：按膀胱癌类型

第 8 章：全球市场分析与预测：按管理途径

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依给药途径，2020-2034年
    • 口服
    • 静脉
    • 膀胱内
  • 市场吸引力：依给药途径分类

第 9 章：全球市场分析与预测：按最终用户

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2020-2034
    • 医院
    • 专科诊所
    • 门诊手术中心
    • 癌症研究机构
  • 市场吸引力：按最终用户划分

第 10 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 11 章：北美市场分析与预测

第 12 章：欧洲市场分析与预测

第 13 章：亚太市场分析与预测

第 14 章：拉丁美洲市场分析与预测

第 15 章：中东和非洲市场分析与预测

第16章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • AstraZeneca
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • Eli Lilly and Company
    • Sanofi SA
    • Genentech, Inc.
Product Code: TMRGL86091

Bladder Cancer Therapeutics Market - Scope of Report

TMR's report on the global bladder cancer therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global bladder cancer therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global bladder cancer therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the bladder cancer therapeutics market.

Market Snapshot
Market Value in 2023US$ 271.4 Mn
Market Value in 2034US$ 456.3 Mn
CAGR4.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global bladder cancer therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global bladder cancer therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global bladder cancer therapeutics market.

The report delves into the competitive landscape of the global bladder cancer therapeutics market. Key players operating in the global bladder cancer therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global bladder cancer therapeutics market profiled in this report.

Key Questions Answered in Global bladder cancer therapeutics Market Report:

  • What is the sales/revenue generated by bladder cancer therapeutics across all regions during the forecast period?
  • What are the opportunities in the global bladder cancer therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Bladder Cancer Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global bladder cancer therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global bladder cancer therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global bladder cancer therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Bladder Cancer Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Bladder Cancer Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Type of Treatment

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type of Treatment, 2020-2034
    • 6.3.1. Chemotherapy
    • 6.3.2. Immunotherapy
    • 6.3.3. Targeted Therapy
    • 6.3.4. Surgery
    • 6.3.5. Radiation Therapy
    • 6.3.6. Others (Combination Therapy, etc.)
  • 6.4. Market Attractiveness, by Type of Treatment

7. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Type of Bladder Cancer

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
    • 7.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
    • 7.3.2. Muscle Invasive Bladder Cancer (MIBC)
  • 7.4. Market Attractiveness, by Type of Bladder Cancer

8. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Oral
    • 8.3.2. Intravenous
    • 8.3.3. Intravesical
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020-2034
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Ambulatory Surgical Centers
    • 9.3.4. Cancer Research Institutes
  • 9.4. Market Attractiveness, by End-user

10. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Bladder Cancer Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type of Treatment, 2020-2034
    • 11.2.1. Chemotherapy
    • 11.2.2. Immunotherapy
    • 11.2.3. Targeted Therapy
    • 11.2.4. Surgery
    • 11.2.5. Radiation Therapy
    • 11.2.6. Others (Combination Therapy, etc.)
  • 11.3. Market Attractiveness, by Type of Treatment
  • 11.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
    • 11.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
    • 11.4.2. Muscle Invasive Bladder Cancer (MIBC)
  • 11.5. Market Attractiveness, by Type of Bladder Cancer
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Oral
    • 11.6.2. Intravenous
    • 11.6.3. Intravesical
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by End-user, 2020-2034
    • 11.8.1. Hospitals
    • 11.8.2. Specialty Clinics
    • 11.8.3. Ambulatory Surgical Centers
    • 11.8.4. Cancer Research Institutes
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Type of Treatment
    • 11.11.2. By Type of Bladder Cancer
    • 11.11.3. By Route of Administration
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Bladder Cancer Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type of Treatment, 2020-2034
    • 12.2.1. Chemotherapy
    • 12.2.2. Immunotherapy
    • 12.2.3. Targeted Therapy
    • 12.2.4. Surgery
    • 12.2.5. Radiation Therapy
    • 12.2.6. Others (Combination Therapy, etc.)
  • 12.3. Market Attractiveness, by Type of Treatment
  • 12.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
    • 12.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
    • 12.4.2. Muscle Invasive Bladder Cancer (MIBC)
  • 12.5. Market Attractiveness, by Type of Bladder Cancer
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Oral
    • 12.6.2. Intravenous
    • 12.6.3. Intravesical
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by End-user, 2020-2034
    • 12.8.1. Hospitals
    • 12.8.2. Specialty Clinics
    • 12.8.3. Ambulatory Surgical Centers
    • 12.8.4. Cancer Research Institutes
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Type of Treatment
    • 12.11.2. By Type of Bladder Cancer
    • 12.11.3. By Route of Administration
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Bladder Cancer Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type of Treatment, 2020-2034
    • 13.2.1. Chemotherapy
    • 13.2.2. Immunotherapy
    • 13.2.3. Targeted Therapy
    • 13.2.4. Surgery
    • 13.2.5. Radiation Therapy
    • 13.2.6. Others (Combination Therapy, etc.)
  • 13.3. Market Attractiveness, by Type of Treatment
  • 13.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
    • 13.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
    • 13.4.2. Muscle Invasive Bladder Cancer (MIBC)
  • 13.5. Market Attractiveness, by Type of Bladder Cancer
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Oral
    • 13.6.2. Intravenous
    • 13.6.3. Intravesical
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by End-user, 2020-2034
    • 13.8.1. Hospitals
    • 13.8.2. Specialty Clinics
    • 13.8.3. Ambulatory Surgical Centers
    • 13.8.4. Cancer Research Institutes
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Type of Treatment
    • 13.11.2. By Type of Bladder Cancer
    • 13.11.3. By Route of Administration
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Bladder Cancer Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Type of Treatment, 2020-2034
    • 14.2.1. Chemotherapy
    • 14.2.2. Immunotherapy
    • 14.2.3. Targeted Therapy
    • 14.2.4. Surgery
    • 14.2.5. Radiation Therapy
    • 14.2.6. Others (Combination Therapy, etc.)
  • 14.3. Market Attractiveness, by Type of Treatment
  • 14.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
    • 14.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
    • 14.4.2. Muscle Invasive Bladder Cancer (MIBC)
  • 14.5. Market Attractiveness, by Type of Bladder Cancer
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Oral
    • 14.6.2. Intravenous
    • 14.6.3. Intravesical
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by End-user, 2020-2034
    • 14.8.1. Hospitals
    • 14.8.2. Specialty Clinics
    • 14.8.3. Ambulatory Surgical Centers
    • 14.8.4. Cancer Research Institutes
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Type of Treatment
    • 14.11.2. By Type of Bladder Cancer
    • 14.11.3. By Route of Administration
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Bladder Cancer Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Type of Treatment, 2020-2034
    • 15.2.1. Chemotherapy
    • 15.2.2. Immunotherapy
    • 15.2.3. Targeted Therapy
    • 15.2.4. Surgery
    • 15.2.5. Radiation Therapy
    • 15.2.6. Others (Combination Therapy, etc.)
  • 15.3. Market Attractiveness, by Type of Treatment
  • 15.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
    • 15.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
    • 15.4.2. Muscle Invasive Bladder Cancer (MIBC)
  • 15.5. Market Attractiveness, by Type of Bladder Cancer
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Oral
    • 15.6.2. Intravenous
    • 15.6.3. Intravesical
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by End-user, 2020-2034
    • 15.8.1. Hospitals
    • 15.8.2. Specialty Clinics
    • 15.8.3. Ambulatory Surgical Centers
    • 15.8.4. Cancer Research Institutes
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Type of Treatment
    • 15.11.2. By Type of Bladder Cancer
    • 15.11.3. By Route of Administration
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Merck & Co., Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Bristol-Myers Squibb Company
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. F. Hoffmann-La Roche AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. AstraZeneca
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Johnson & Johnson
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Pfizer Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Novartis AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Eli Lilly and Company
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Sanofi S.A.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Genentech, Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
  • Table 02: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
  • Table 03: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 04: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 06: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 07: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
  • Table 08: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
  • Table 09: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 11: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
  • Table 13: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
  • Table 14: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 16: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
  • Table 18: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
  • Table 19: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 21: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
  • Table 23: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
  • Table 24: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 26: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Treatment, 2020-2034
  • Table 28: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Type of Bladder Cancer, 2020-2034
  • Table 29: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Bladder Cancer Therapeutics Market Size (US$ Mn), by Region, 2023 and 2034
  • Figure 02: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by Type of Treatment, 2023
  • Figure 03: Global Bladder Cancer Therapeutics Market Value Share, by Type of Treatment, 2023
  • Figure 04: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by Type of Bladder Cancer, 2023
  • Figure 05: Global Bladder Cancer Therapeutics Market Value Share, by Type of Bladder Cancer, 2023
  • Figure 06: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2023
  • Figure 07: Global Bladder Cancer Therapeutics Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by End-user, 2023
  • Figure 09: Global Bladder Cancer Therapeutics Market Value Share, by End-user, 2023
  • Figure 10: Global Bladder Cancer Therapeutics Market Value Share, by Region, 2023
  • Figure 11: Global Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 12: Global Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
  • Figure 13: Global Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
  • Figure 14: Global Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
  • Figure 15: Global Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
  • Figure 16: Global Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Bladder Cancer Therapeutics Market Revenue (US$ Mn), by End-user, 2023
  • Figure 19: Global Bladder Cancer Therapeutics Market Value Share, by End-user, 2023
  • Figure 20: Global Bladder Cancer Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Bladder Cancer Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Bladder Cancer Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
  • Figure 26: North America Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
  • Figure 27: North America Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 29: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
  • Figure 30: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
  • Figure 31: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
  • Figure 37: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
  • Figure 38: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
  • Figure 41: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
  • Figure 42: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
  • Figure 48: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
  • Figure 49: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
  • Figure 52: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
  • Figure 53: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Bladder Cancer Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
  • Figure 59: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
  • Figure 60: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
  • Figure 63: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
  • Figure 64: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Bladder Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Treatment, 2023 and 2034
  • Figure 70: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by Type of Bladder Cancer, 2023 and 2034
  • Figure 71: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Bladder Cancer Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 73: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Treatment, 2024-2034
  • Figure 74: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by Type of Bladder Cancer, 2024-2034
  • Figure 75: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Bladder Cancer Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034